Compare DigitalOcean Holdings Inc (DOCN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DigitalOcean Holdings Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? DigitalOcean Holdings Inc trades at $134.82 (market cap $14.57B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 8.8× DigitalOcean Holdings Inc's market cap, and DigitalOcean Holdings Inc is more actively traded (2,261,786 versus 1,487,944). Which is the better fit depends on your goals — on Pluang, investors hold DigitalOcean Holdings Inc for 43 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| DOCN | VRTX | |
|---|---|---|
Market Cap | $14.57B | $127.55B |
Volume | 2,261,786 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $181.29 | $557.96 |
52-Week Low | $37.30 | $407.37 |
Typical Hold Time | 43 Days | 120 Days |
Enterprise Value | $15.33B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DigitalOcean (DOCN) trades at $134.82, up 5.92% today, showing strong momentum with three consecutive quarterly earnings beats. The stock exhibits bullish technical signals with RSI levels in oversold territory, while fundamentals reveal impressive revenue growth from $576M in 2022 to $901M in 2025, with net income turning positive at $259M. Recent announcements include new AI-focused Agent Droplets and a $725M equipment financing facility to support capacity expansion.
DOCN presents growth potential with strong analyst support (68% buy ratings) and a $172.73 consensus price target, though elevated valuation ratios (P/E 56.32, P/S 13.96) and negative shareholder equity pose risks. The company's AI-native cloud strategy shows promise, but execution risks and competitive pressures in the cloud infrastructure space require monitoring.
Vertex Pharmaceuticals (VRTX) trades at $510.08, up 0.88% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $12B revenue and $4B net income, though recent quarterly earnings show inconsistent performance against expectations. Positive Phase 2b data for inaxaplin in kidney disease highlights pipeline progress beyond cystic fibrosis dominance.
Wall Street maintains strong bullish sentiment with 84% buy ratings and $573.50 consensus target, but risks include competitive pressures and reliance on CF franchise. The stock's premium valuation (P/E 29.31) requires continued execution on pipeline expansion to justify upside potential amid technical resistance near $515.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
